Evidence map›Paper›PMID 40584622›Full record

ArticleFrontiers in pharmacology2025

Sijing Liu, Yongli Situ, Li Deng, Meng Liang, Haoyuan He, Zheng Shao, Lifei Peng

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sijing LiuDepartment of Orthopaedic Center, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, China.
Yongli SituDepartment of Parasitology, Guangdong Medical University, Dongguan, China.
Li DengInstitute of Pathogenic Biology and Immunology, Guangdong Medical University, Dongguan, China.
Meng LiangInstitute of Pathogenic Biology and Immunology, Guangdong Medical University, Dongguan, China.
Haoyuan HeDepartment of Orthopaedic Center, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, China.
Zheng ShaoInstitute of Pathogenic Biology and Immunology, Guangdong Medical University, Dongguan, China.
Lifei PengDepartment of Parasitology, Guangdong Medical University, Dongguan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gout, a prevalent and severe form of arthritis precipitated by hyperuricemia, has been the subject of extensive research. However, the intricate underlying mechanisms governing gout-related inflammation are still only partially elucidated. Methods: The CPI2 fusion protein was induced for expression in Results: After culturing in Conclusion: CPI2 alleviates MSU-induced acute gouty arthritis in mice through the inhibition of cathepsin S and the C5a - C5aR1 axis. CPI2 may represent a potential candidate for the treatment of gouty arthritis.

Indexed as

C5a-C5aR1 axiscathepsin Scysteine protease inhibitorgouty arthritismice

Identifiers

PMID40584622
PMCPMC12202429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.